Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vena caval filters: a comprehensive review.

M B Streiff1

  • 1Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. mstreiff@jhmi.edu

Blood
|June 14, 2000
PubMed
Summary

Vena caval filters help prevent pulmonary embolism but have risks like thrombosis. More randomized trials are needed to determine their safety and effectiveness compared to anticoagulation for venous thromboembolic disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Two Consecutive Invasive Surgeries Utilizing Zymogen Protein C (ZPC) That Enhanced Patient Safety and Reduced Costs.

Advances in experimental medicine and biology·2021
Same author

A novel diagnostic algorithm for heparin-induced thrombocytopenia.

International journal of laboratory hematology·2018
Same author

A Compelling Case for the Use of Perioperative Zymogen Protein C for Increased Patient Safety.

Advances in experimental medicine and biology·2016
Same author

Retrospective cohort study comparing activated partial thromboplastin time versus anti-factor Xa activity nomograms for therapeutic unfractionated heparin monitoring in pediatrics.

Journal of thrombosis and haemostasis : JTH·2015
Same author

Venous thromboembolism incidence in the Cooperative Study of Sickle Cell Disease.

Journal of thrombosis and haemostasis : JTH·2014
Same author

Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2014

Area of Science:

  • Medical research
  • Hematology
  • Vascular surgery

Background:

  • Venous thromboembolic disease is common, with anticoagulation as the primary treatment.
  • Vena caval filters serve as an alternative when anticoagulants are contraindicated.
  • Evidence for vena caval filter utility is primarily from case series, lacking robust randomized trials.

Purpose of the Study:

  • To review the English language literature on vena caval filters for venous thromboembolic disease.
  • To assess the efficacy and safety of different vena caval filter types.
  • To identify the need for further research, particularly randomized trials.

Main Methods:

  • Comprehensive literature review of English language studies on vena caval filters.
  • Analysis of data from case series and one randomized trial.
  • Evaluation of filter efficacy in preventing pulmonary embolism and incidence of deep vein thrombosis and vena cava thrombosis.

Main Results:

  • All five filter types showed similar efficacy in preventing pulmonary embolism (2.6%-3.8%).
  • Deep vein thrombosis (6%-32%) and inferior vena cava thrombosis (3.6%-11.2%) rates varied widely.
  • Thrombosis at the insertion site was a frequent complication (23%-36%).

Conclusions:

  • Vena caval filters are a potentially important but inadequately evaluated treatment for pulmonary embolism prevention.
  • No specific filter type is demonstrably superior in safety or efficacy due to a lack of randomized comparisons.
  • Randomized trials are essential to define the optimal role of vena caval filters in managing venous thromboembolic disease.

Related Experiment Videos